On December 28, 2023, the FDA Informed MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued. This Clinical Hold letter rejects the …
MAPS’ proposed Study MJP2 study is a research study that is intended to add to the cannabis safety literature and contribute to a better understanding of the safety and effectiveness of real-world …
On August 11, the FDA Division of Pulmonology, Allergy, and Critical Care (DPACC) sent MAPS additional guidance on the safety of smoking in naïve subjects in MJP2. The FDA’s correspondence was a …
On July 12, 2023, the FDA Division of Psychiatry sent MAPS the official minutes of our Type A meeting on June 15, 2023. The Type A meeting focused on the issues the FDA cited in its Clinical Hold on the …
After reviewing MAPS’ Type A Meeting Request and Briefing submitted on April 28, the FDA granted MAPS’ meeting request. MAPS and the FDA will have a face-to-face formal meeting to discuss the …
On April 28, 2023, MAPS requested the FDA for a Type A meeting to discuss the clinical hold issues for Study MJP2 in order to overcome the clinical hold deficiencies. This meeting request is in response …
Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
On April 8, 1986—36 years ago today—the Multidisciplinary Association for Psychedelic Studies (MAPS) was founded by Rick Doblin, Ph.D., as a non-profit organization to fulfill the need to broaden psychedelic …
Summary: Berra Yazar-Klosinski, Ph.D., of MAPS and MAPS Public Benefit Corporation (MAPS PBC) joins Northstar Sleep School’s podcast to share progress updates about MAPS’ research and consider …
Summary: Pharmacy Times interviews Bia Labate, Ph.D., of MAPS and Chacruna Institute and psychiatric pharmacist Kelan Thomas, Pharm.D., M.S., about the significant scale of current clinical trials involving …
Summary: Listen to MAPS Founder and Executive Director Rick Doblin, Ph.D., on The Recount’s Hell & High Water podcast, where he and John Heilemann discuss exciting developments in the field …
Summary: Listen to MAPS Founder and Executive Director Rick Doblin, Ph.D., on the Drug Science Podcast, where he speaks with Professor David Nutt about MAPS’ 35-year history, current project updates, …
